Loading stock data…
$10.06+0.26 (+2.70%)
ImmunityBio, Inc., a biotechnology company, focuses on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient's immune system and deliver durable protection against cancer and infectious diseases.
ImmunityBio, Inc. in the Healthcare sector is trading at $10.06 with a market capitalization of $8.9B. Wall Street consensus targets $12.75 (4 analysts), implying a +26.7% move over the next 12 months. The stock is currently 19% below its 52-week high of $12.43, remaining 33.8% above its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 85/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $51.24M↑ | $44.21M↑ | $38.28M↑ | $32.06M↑ | $26.43M |
| Gross Profit | $50.94M↑ | $43.97M↑ | $37.90M↑ | $31.88M↑ | $26.29M |
| Operating Income | -$61.70M↑ | -$69.79M↓ | -$64.68M↓ | -$55.63M↑ | -$71.28M |
| Net Income | -$230.38M↑ | -$632.78M↓ | -$61.94M↑ | -$67.25M↑ | -$92.56M |
ImmunityBio, Inc., a biotechnology company, focuses on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient's immune system and deliver durable protection against cancer and infectious diseases....